PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Revenue of PepGen Inc. (PEPG)
Revenue in 2023 (TTM): $
According to PepGen Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of PepGen Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,184,000 | $-83,582,000 | $-78,553,000 | $-78,626,000 |
| 2022 | $ | $-493,000 | $-67,808,000 | $-65,398,000 | $-69,104,000 |
| 2021 | $ | $-178,000 | $-26,931,000 | $-27,281,000 | $-27,281,000 |
| 2020 | $ | $-110,000 | $-1,767,000 | $-1,889,000 | $-1,881,000 |
| 2019 | $ | $-106,000 | $-1,248,000 | $-1,346,000 | $-1,346,000 |